Skip to content
Sulindac
Clinoril (sulindac) is a small molecule pharmaceutical. Sulindac was first approved as Clinoril on 1982-01-01. It is used to treat ankylosing spondylitis, bursitis, gouty arthritis, inflammation, and osteoarthritis amongst others in the USA. It is known to target prostaglandin G/H synthase 2, retinoic acid receptor RXR-alpha, and prostaglandin G/H synthase 1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
nutritional and metabolic diseasesD009750
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
wounds and injuriesD014947
psychological phenomenaD011579
musculoskeletal and neural physiological phenomenaD055687
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sulindac
Tradename
Company
Number
Date
Products
CLINORILMerck KGaAN-017911 DISCN1982-01-01
2 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
sulindacANDA2023-05-22
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
ankylosing spondylitisEFO_0003898D013167M45
bursitisEFO_1000941D002062M71.9
gouty arthritisD015210
inflammationMP_0001845D007249
osteoarthritisEFO_0002506D010003M15-M19
rheumatoid arthritisEFO_0000685D001172M06.9
shoulder painHP_0030834D020069M25.51
tendinopathyEFO_1001434D052256M77.9
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
M: Musculo-skeletal system drugs
M01: Antiinflammatory and antirheumatic products
M01A: Antiinflammatory and antirheumatic products, non-steroids
M01AB: Acetic acid derivatives and related substances
M01AB02: Sulindac
HCPCS
No data
Clinical
Clinical Trials
75 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C50242916
Acne vulgarisD000152EFO_0003894L70112
Wounds and injuriesD014947T14.811
Crohn diseaseD003424EFO_0000384K5011
Sentinel lymph node biopsyD02170111
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Brain hypoxia-ischemiaD020925EFO_1000846P91.622
StrokeD020521EFO_0000712I63.9112
Covid-19D000086382U07.111
Necrotizing enterocolitisD020345EFO_0003928K55.311
Heart diseasesD006331EFO_0003777I51.911
Retinal detachmentD012163EFO_0005773H33.211
Proliferative vitreoretinopathyD018630EFO_100112911
Brain diseasesD001927HP_0001298G93.4011
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Kidney neoplasmsD007680EFO_0003865C64112
LymphedemaD008209Q82.0112
Portal hypertensionD006975EFO_0000666K76.611
Non-small-cell lung carcinomaD00228911
Chronic renal insufficiencyD051436N1811
Urinary tract infectionsD014552EFO_0003103N39.011
Vesico-ureteral refluxD014718EFO_0007536N13.711
Tetralogy of fallotD013771Q21.3111
Pulmonary valve insufficiencyD011665111
Renal cell carcinomaD00229211
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cystic fibrosisD003550EFO_0000390E84112
Liver cirrhosisD008103EFO_0001422K74.011
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.8111
AppendicitisD001064EFO_0007149K3711
Ciliary motility disordersD002925EFO_000390011
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients22
Rectal neoplasmsD01200422
Liver neoplasmsD008113EFO_1001513C22.022
Head and neck neoplasmsD00625822
NeoplasmsD009369C8011
MelanomaD00854511
Squamous cell carcinoma of head and neckD00007719511
Uterine cervical neoplasmsD00258311
Ulcerative colitisD003093EFO_0000729K5111
Feeding behaviorD00524711
Show 15 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSULINDAC
INNsulindac
Description
Sulindac is a monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions. It has a role as a non-steroidal anti-inflammatory drug, an EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor, an antineoplastic agent, a non-narcotic analgesic, an antipyretic, an analgesic, a prodrug, a tocolytic agent and an apoptosis inducer. It is a sulfoxide, a monocarboxylic acid and an organofluorine compound. It is functionally related to an acetic acid.
Classification
Small molecule
Drug classanti-inflammatory agents (acetic acid derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S+](C)[O-])cc1
Identifiers
PDB
CAS-ID38194-50-2
RxCUI10237
ChEMBL IDCHEMBL15770
ChEBI ID9352
PubChem CID1548887
DrugBankDB00605
UNII ID184SNS8VUH (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
PTGS2
PTGS2
RXRA
RXRA
PTGS1
PTGS1
Organism
Homo sapiens
Gene name
PTGS2
Gene synonyms
COX2
NCBI Gene ID
Protein name
prostaglandin G/H synthase 2
Protein synonyms
COX-2, cyclooxygenase 2, cyclooxygenase 2b, Cyclooxygenase-2, PGH synthase 2, PGHS-2, PHS II, Prostaglandin H2 synthase 2, Prostaglandin-endoperoxide synthase 2, prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)
Uniprot ID
Mouse ortholog
Ptgs2 (19225)
prostaglandin G/H synthase 2 (Q543K3)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 5,976 documents
View more details
Safety
Black-box Warning
Black-box warning for: Sulindac
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details